Stifel analyst Stephen Willey downgraded Vor Bio (VOR) to Hold from Buy with a price target of 30c, down from $5, following the company’s decision to explore a range of strategic alternatives in an effort to maximize shareholder value. The decision reflects a combination of both clinical data evaluated to date and the challenging financing environment currently characterizing the biotech sector, the analyst tells investors in a research note.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VOR: